CN110769819A - 用于治疗痤疮的大麻素制剂 - Google Patents

用于治疗痤疮的大麻素制剂 Download PDF

Info

Publication number
CN110769819A
CN110769819A CN201880023591.0A CN201880023591A CN110769819A CN 110769819 A CN110769819 A CN 110769819A CN 201880023591 A CN201880023591 A CN 201880023591A CN 110769819 A CN110769819 A CN 110769819A
Authority
CN
China
Prior art keywords
cbd
skin
pharmaceutical composition
group
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880023591.0A
Other languages
English (en)
Chinese (zh)
Inventor
E.库珀
M.卡拉汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Botanix Pharmaceuticals Ltd
Original Assignee
Botanix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900493A external-priority patent/AU2017900493A0/en
Application filed by Botanix Pharmaceuticals Ltd filed Critical Botanix Pharmaceuticals Ltd
Priority claimed from PCT/AU2018/050045 external-priority patent/WO2018148786A1/en
Publication of CN110769819A publication Critical patent/CN110769819A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
CN201880023591.0A 2017-02-15 2018-01-24 用于治疗痤疮的大麻素制剂 Pending CN110769819A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762459313P 2017-02-15 2017-02-15
US62/459,313 2017-02-15
AU2017900493A AU2017900493A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Acne
AU2017900493 2017-02-15
PCT/AU2018/050045 WO2018148786A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Publications (1)

Publication Number Publication Date
CN110769819A true CN110769819A (zh) 2020-02-07

Family

ID=67766784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880023591.0A Pending CN110769819A (zh) 2017-02-15 2018-01-24 用于治疗痤疮的大麻素制剂

Country Status (9)

Country Link
US (1) US20220323401A1 (enExample)
EP (1) EP3582770A4 (enExample)
JP (2) JP2020508992A (enExample)
CN (1) CN110769819A (enExample)
AU (1) AU2018221881B2 (enExample)
BR (1) BR112019017049A2 (enExample)
CA (1) CA3053503C (enExample)
IL (1) IL268728B2 (enExample)
NZ (1) NZ756307A (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372196A (zh) * 2021-07-02 2021-09-10 江南大学 8,9-二氢大麻二酚及其合成方法与应用
CN114073687A (zh) * 2020-08-21 2022-02-22 四川大学华西医院 大麻二酚在制备防治玫瑰痤疮的药物中的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017049A2 (pt) * 2017-02-15 2020-04-14 Botanix Pharmaceuticals Ltd formulações de canabinoides para o tratamento de acne
EP4111193A4 (en) * 2020-02-25 2024-04-03 Advanced Animal Diagnostics, Inc. METHODS AND COMPOSITIONS FOR IDENTIFYING A SURVIVAL INDEX FOR AN ANIMAL
JP7736306B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736309B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736310B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736308B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273895A1 (en) * 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
CN103796637A (zh) * 2011-07-05 2014-05-14 韦特股份有限公司 大麻素受体结合剂、组合物以及方法
US20160256410A1 (en) * 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
DE60228713D1 (de) * 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2009090495A2 (en) * 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
HUE026929T2 (en) * 2010-10-19 2016-08-29 Parenteral A S A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
WO2014074289A1 (en) * 2012-11-06 2014-05-15 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
WO2014116653A1 (en) * 2013-01-22 2014-07-31 Coty Inc. Topical formulations and methods for the use thereof
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
BR112019017049A2 (pt) * 2017-02-15 2020-04-14 Botanix Pharmaceuticals Ltd formulações de canabinoides para o tratamento de acne
CA3053500A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273895A1 (en) * 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
CN103796637A (zh) * 2011-07-05 2014-05-14 韦特股份有限公司 大麻素受体结合剂、组合物以及方法
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US20160256410A1 (en) * 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATTILA OLÁH等: "Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
ATTILA OLÁH等: "Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment", 《EXPERIMENTAL DERMATOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114073687A (zh) * 2020-08-21 2022-02-22 四川大学华西医院 大麻二酚在制备防治玫瑰痤疮的药物中的用途
CN113372196A (zh) * 2021-07-02 2021-09-10 江南大学 8,9-二氢大麻二酚及其合成方法与应用
CN113372196B (zh) * 2021-07-02 2022-09-30 江南大学 8,9-二氢大麻二酚及其合成方法与应用

Also Published As

Publication number Publication date
JP2020508992A (ja) 2020-03-26
JP2022185150A (ja) 2022-12-13
AU2018221881B2 (en) 2023-09-14
US20220323401A1 (en) 2022-10-13
CA3053503A1 (en) 2018-08-23
CA3053503C (en) 2024-04-23
AU2018221881A1 (en) 2019-09-05
BR112019017049A2 (pt) 2020-04-14
EP3582770A1 (en) 2019-12-25
EP3582770A4 (en) 2020-11-18
IL268728A (en) 2019-10-31
IL268728B2 (en) 2024-09-01
IL268728B1 (en) 2024-05-01
NZ756307A (en) 2023-01-27

Similar Documents

Publication Publication Date Title
JP2022185150A (ja) ざ瘡の処置のためのカンナビノイドの製剤
CN110545807B (zh) 用于治疗皮炎和炎性皮肤病的大麻素制剂
WO2018148786A1 (en) Formulations of cannabinoids for the treatment of acne
WO2018148785A1 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018148787A1 (en) Formulations of cannabinoids for the treatment of psoriasis
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
US20240325393A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
JP2024012288A (ja) ざ瘡のためのカンナビノイド投薬レジメン
US20230037905A1 (en) Topical composition comprising tofacitinib and fingolimod
CN110520123A (zh) 用于治疗银屑病的大麻素制剂
US20220331269A1 (en) Compositions for treating acne

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination